A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease

NCT06175767 | Not Yet Recruiting Phase 2 DMC FDA Drug

• 1 other identifier: MT101-PD-002
• Study Type: interventional
• Target: 120
• Locations: 0 countries
• Sites: N/A

Brief Summary

A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease. Primary objective of the study is to evaluate the safety and tolerability of MT101-5 400 mg and 600 mg oral tablet total daily dose compared to Placebo in subjects with Parkinson's Disease.

Conditions

Parkinson's Disease

Outcome Measures

Primary Outcomes (12)

• Incidence of Treatment-Emergent Adverse Events (TEAEs)

  An adverse event (AE) is defined as any unfavorable or unintended sign, symptom, or disease that occurs or is reported by the patient to have occurred, or a worsening of a pre-existing condition. An adverse event may or may not be related to the study treatment.

  Change from baseline to week 12 after the first study drug administration

• Incidence of withdrawals due to Adverse Events (AEs)

  Incidence of withdrawals due to Adverse Events (AEs) defined above

  Change from baseline to week 12 after the first study drug administration

• Incidence of serious adverse events (SAEs)

  Adverse event that results in death, is life threatening, Requires subject hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.

  Change from baseline to week 12 after the first study drug administration

• Columbia-Suicide Severity Rating Scale (C-SSRS)

  Suicidal ideation/suicidal behavior assessment tool. Score ranges from 2 to 25, with the higher number indicating more intense ideation.

  Change from baseline to week 12 after the first study drug administration

• Change of blood pressure (both systolic and diastolic blood pressures)

  Change from baseline to week 12 after the first study drug administration

• Change of body temperature

  Change from baseline to week 12 after the first study drug administration

• Change of respiratory rate

  Change from baseline to week 12 after the first study drug administration

• ECG ventricular rate (beats per minute)

  Change from baseline to week 12 after the first study drug administration

• ECG PR interval (msec)

  Change from baseline to week 12 after the first study drug administration

• ECG QRS interval (msec)

  Change from baseline to week 12 after the first study drug administration

• ECG QT interval (msec)

  Change from baseline to week 12 after the first study drug administration

• ECG QTc interval (msec)

  Change from baseline to week 12 after the first study drug administration

Secondary Outcomes (5)

• Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) total score

  Change from baseline to week 12 after the first study drug administration

• Schwab and England (S&E) Scale total score

  Change from baseline to week 12 after the first study drug administration

• Parkinson's Disease Questionnaire (PDQ-39) total score

  Change from baseline to week 12 after the first study drug administration

• Hoehn and Yahr (H&Y) scale total score

  Change from baseline to week 12 after the first study drug administration

• Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scale score.

  Change from baseline to week 12 after the first study drug administration

Other Outcomes (2)

• Change from baseline of CSF levels of alpha-synuclein

  Change from baseline to week 12 after the first study drug administration

• Discovery of biomarkers for MT101-5 as significant DEPs (differentially expressed proteins) with >2-fold change between MT101 and PD patient groups.

  Change from baseline to week 12 after the first study drug administration

Study Arms (3)

Screening Phase (Day -28 to Day -1, up to 28 days):

EXPERIMENTAL

Screening phase is designed to determine subject's eligibility to proceed to Randomization and the Treatment Phase of the study. During this phase, a series of assessments will be performed to determine subject eligibility as per inclusion and exclusion criteria. Subjects who meet eligibility criteria, but have some abnormal laboratory values, based on PI review a repeat laboratory sample may be collected. The repeat laboratory reports should be reviewed by the PI to confirm eligibility prior to randomization. Subjects who fail to meet eligibility criteria during the Screening phase will be considered screen failures and will be exited from the study. Subjects who meet the eligibility criteria will be scheduled for randomization visit.

Drug: MT101-5

Randomization and Double-Blind Treatment Phase (TV0- TV3, 12 weeks):

EXPERIMENTAL

Subjects who have successfully completed the Screening phase will enter the Randomization and Double-Blind treatment phase of the study. Subjects will take the assigned randomized treatment, MT101-5 at 400 mg, 600 mg or placebo for 12 weeks. MT101-5 and matching placebo are oral tablets that will be taken as six tablets two times a day (b.i.d.) at least 2 hours before or 2 hours after meal in the morning and evening daily during this study.

Drug: MT101-5

Follow-up Phase (FUV, 4 weeks ± 3 days)

EXPERIMENTAL

The follow-up phase will consist of a follow-up visit at the end of the Double-Blind Treatment phase.

Drug: MT101-5

Interventions

MT101-5 DRUG

Tablet

Follow-up Phase (FUV, 4 weeks ± 3 days); Randomization and Double-Blind Treatment Phase (TV0- TV3, 12 weeks):; Screening Phase (Day -28 to Day -1, up to 28 days):

Eligibility Criteria

• Age: 30 Years - 79 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects will be eligible for enrollment in the study only if they meet ALL of the following criteria:
• Male or female subjects who are between 30 and 79 years old inclusive with a clinical diagnosis of Parkinson's disease as per UK Brain Bank Criteria for two (2) years or less at screening.
• Hoehn and Yahr I or II at screening.
• Subjects who are newly diagnosed \& currently not on any Parkinson's disease medication (or) subjects who are on stable doses for at least 4 weeks prior to screening on Amantadine or anticholinergics for treatment of Parkinson's disease (1) Note: Subjects that had anti-parkinsonian medication (including levodopa, dopamine agonists, entacapone and monoamine oxidase-B inhibitors) discontinued at least 60 days prior to screening, e.g., for intolerance, may be considered eligible if all other eligibility requirements are met.
• Without clinically significant abnormalities in physical exam, neurological exam and laboratory assessments (urine/blood routine, biochemical tests and ECG) which would exclude the subject from the study in the opinion of the Investigator. For aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) the screening levels should be ≤ 2 times upper limit normal.
• Subject is capable of providing informed consent and is willing to sign the ICF prior to study Screening and agrees to comply with the study protocol requirements.

You may not qualify if:

• Subjects will be eligible for enrollment in the study only if they meet NONE of the following criteria:
• Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or degenerative disease).
• Subjects with history of neurosurgical intervention for Parkinson's disease.
• Subjects who meet the DSM-V criteria at screening for bipolar disorder, major depressive disorder, psychotic disorders, or any other comorbid mental disorders that in the opinion of the Investigator may interfere with study conduct and results interpretation.
• Subjects with clinical diagnosis of dementia (MMSE score \<24) as determined by the investigator using Mini-Mental State Examination (MMSE).
• Female subjects who are pregnant or breast feeding.
• Initiation of any anti-parkinsonian medication (including levodopa, dopamine agonists, entacapone and monoamine oxidase-B inhibitors) for the duration of the trial.
• Initiation of Amantadine or anticholinergics for newly diagnosed subjects or change in the dosage of Amantadine or anticholinergics during the trial for subjects who were on stable doses for 4 weeks prior to screening.
• Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.
• Subjects who used investigational drugs or devices within 60 days prior to screening or investigational biologics within the last 6 months prior to screening.
• Subjects with a clinically significant medical or surgical condition, including major surgeries within 28 days prior to enrollment.
• The subject has a known allergy or hypersensitivity to any component of the formulation.
• The subject has a history of alcohol abuse (defined as an alcohol intake more than 21 units per week) or a history of drug abuse within the 6 months before study drug administration, or a history of substance abuse deemed significant by the investigator. A unit of alcohol is defined as 240 mL of beer, 120 mL of wine, or 1 single shot of spirits.
• Women of child-bearing age who are sexually active but decline to take proper contraceptive measures during the study period
• Note: To be eligible for the study, Women of childbearing potential (WOCBP) and Women not of childbearing potential are eligible to participate. Both women of childbearing potential and women of no childbearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study (and for 30 days after taking the last dose of investigational product).

Sponsors & Collaborators

• Mthera Pharma Co., Ltd.: lead

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Central Study Contacts

Anandkrishnan Balasubramanian

CONTACT

(301) 956-2531; anandb@amarexcro.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, CARE PROVIDER
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 22, 2023
• First Posted: December 19, 2023
• Study Start: March 14, 2025
• Primary Completion: July 1, 2025
• Study Completion: September 1, 2025
• Last Updated: November 25, 2024

Record last verified: 2024-11